These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 6818701)

  • 21. A Canadian survey of self-infusion practices in persons with haemophilia A.
    Teitel J; Belliveau D; Blanchette V; Chan A; Klaassen R; Price V; Ritchie B; Wu J
    Haemophilia; 2012 Nov; 18(6):e403-5. PubMed ID: 23106946
    [No Abstract]   [Full Text] [Related]  

  • 22. Pharmacokinetics of factor VIII in hemophilia A patients assessed by frequency response method.
    Durisová M; Dedík L; Bátorová A; Sakalová A; Hedera J
    Methods Find Exp Clin Pharmacol; 1998 Apr; 20(3):217-26. PubMed ID: 9646284
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recombinant factor VIII in hemophilia A: the Canadian experience.
    Blanchette VS
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S33-9. PubMed ID: 9351535
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of patients with hemophilia A and inhibitors to factor FVIII with cimetidine.
    Ambriz Fernandez R; Quintana Gonzalez S; Martinez Murillo C; Dominguez Garcia V; Rodriguez Moyado H; Collazo Jaloma J
    Arch Med Res; 1996; 27(1):15-8. PubMed ID: 8867361
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of hemorrhage in hemophilia.
    Med Lett Drugs Ther; 1967 Apr; 9(8):31-2. PubMed ID: 6040171
    [No Abstract]   [Full Text] [Related]  

  • 26. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa.
    Hedner U
    Thromb Haemost; 1999 Aug; 82(2):531-9. PubMed ID: 10605747
    [No Abstract]   [Full Text] [Related]  

  • 27. Hemostasis. II. The use of factor VIII concentrates in the therapy of hemophilia.
    Davis RB
    Nebr State Med J; 1971 Jun; 56(6):219-24. PubMed ID: 4253029
    [No Abstract]   [Full Text] [Related]  

  • 28. Fifteen years of population based experience in Finland with a plasma-derived monoclonal purified factor VIII concentrate.
    Mäkipernaa A; von Bonsdorff L
    Haemophilia; 2008 May; 14(3):612-4. PubMed ID: 18312362
    [No Abstract]   [Full Text] [Related]  

  • 29. [Preparation and use of factor VIII concentrates in hemophilia].
    Vilar JM; Ortega F; Martin-Arias DM; Vazquez J; Navarro JL
    Sangre (Barc); 1969; 14(1):57-64. PubMed ID: 5792112
    [No Abstract]   [Full Text] [Related]  

  • 30. [Self treatment of hemophiliacs].
    Med Monatsschr; 1971 Sep; 25(9):393-4. PubMed ID: 5110347
    [No Abstract]   [Full Text] [Related]  

  • 31. [Prophylaxis in hemophilia].
    Ortega F; Martin-Villar J; Navarro JL
    Sangre (Barc); 1970; 15(3):355-61. PubMed ID: 5486763
    [No Abstract]   [Full Text] [Related]  

  • 32. [Poly-electrolyte fractionated porcine factor VIII in the treatment of hemophilia A].
    Ferencz T; Skopál J; Csáki C; Laczkó M; Schuler D; Borsi J
    Orv Hetil; 1993 Dec; 134(52):2873-5. PubMed ID: 8272354
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New treatment for hemophilia.
    FDA Consum; 2003; 37(6):5. PubMed ID: 14983810
    [No Abstract]   [Full Text] [Related]  

  • 34. Porcine factor VIII therapy in patients with congenital hemophilia and inhibitors: efficacy, patient selection, and side effects.
    Hay CR; Lozier JN; Lee CA; Lafan M; Tradati H; Santagostino E; Ciavarella N; Schiavoni M; Fukui H; Yoshioka A
    Semin Hematol; 1994 Apr; 31(2 Suppl 4):20-5. PubMed ID: 7939768
    [No Abstract]   [Full Text] [Related]  

  • 35. Prophylaxis in children with hemophilia: is it the optimal treatment?
    Lusher JM
    Thromb Haemost; 1997 Jul; 78(1):726-9. PubMed ID: 9198246
    [No Abstract]   [Full Text] [Related]  

  • 36. Factor VIII inhibitor and severity of hemophilia.
    Schoppmann A; Waytes AT
    Thromb Haemost; 1996 Aug; 76(2):280-1. PubMed ID: 8865549
    [No Abstract]   [Full Text] [Related]  

  • 37. Hemophilia with factor VIII and factor IX inhibitors, incidence, bleeding problems and management.
    Mahasandana C; Patharathienskul D; Suvatte V
    Southeast Asian J Trop Med Public Health; 1993; 24 Suppl 1():106-12. PubMed ID: 7886549
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors.
    Santagostino E; Morfini M; Rocino A; Baudo F; Scaraggi FA; Gringeri A
    Thromb Haemost; 2001 Oct; 86(4):954-8. PubMed ID: 11686352
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of the immunogenicity of different therapeutic preparations of human factor VIII in the murine model of hemophilia A.
    Delignat S; Dasgupta S; André S; Navarrete AM; Kaveri SV; Bayry J; André MH; Chtourou S; Tellier Z; Lacroix-Desmazes S
    Haematologica; 2007 Oct; 92(10):1423-6. PubMed ID: 18024377
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Opportune treatment of hemorrhage in classical hemophilia. Study of the Hemophilia Cooperative Group].
    Rodríguez-Moyado H; Ambriz-Fernández R; Pizzuto-Chávez J; Farfán-Canto JM; Hernández-Lugo MI; Guillén-Mariscal C; Ramírez-Ortiz G; Benítez-Aranda H
    Bol Med Hosp Infant Mex; 1986 Dec; 43(12):742-9. PubMed ID: 3101718
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.